Target intelligence / Profile preview

Intestinal bacterium

Molecular classification
Other
01

Overview

Intestinal bacteria, collectively known as gut microbiota or gut flora, constitute a complex and dynamic community of mostly bacteria residing in the human gastrointestinal tract. They play critical roles in metabolism, immune modulation, protection from pathogens, and maintenance of intestinal integrity. The microbiota is dominated by two phyla, Firmicutes and Bacteroidetes, but also includes Actinobacteria, Proteobacteria, and others. There are thousands of bacterial species, but the functional capacity of the microbiota is often more conserved than its precise taxonomic composition. Disruptions in the intestinal microbiota (dysbiosis) are linked to various diseases, including inflammatory, infectious, metabolic, and neoplastic disorders. Note: "Intestinal bacteria" is not a single molecule, protein, or receptor, and thus does not conform to standard definitions of a therapeutic "target". The use of this term as a therapeutic or pharmacological target is scientifically imprecise and should instead refer to a specific bacterial genus, species, or molecular component.

Other names
intestinal microbiotagut bacteriagut microbiotagut floragastrointestinal bacteria
02

Mechanism of action

Modification of community composition (e.g., with antibiotics, probiotics) Suppression of pathogenic bacteria Stimulation of beneficial metabolite production

03

Biological functions

Digestion of complex carbohydratesSynthesis of vitamins (e.g., vitamin K, some B vitamins)Fermentation to produce short-chain fatty acids (such as butyrate, acetate, propionate)Modulation of immune responseMaintenance of intestinal barrier integrityBiotransformation of bile acids and xenobioticsProtection against pathogenic microorganisms
04

Disease associations

Inflammatory bowel diseaseIrritable bowel syndromeMetabolic syndromeObesityCancer (notably colorectal cancer)InfectionOther (many chronic and systemic diseases are influenced by gut microbiota composition)
05

Safety considerations

Risk of infection (opportunistic pathogenic bacteria)Disruption by antibiotics leading to dysbiosisTransfer of antibiotic resistance genesRisks associated with fecal microbiota transplantation
06

Interacting drugs

Antibiotics (impact community composition)

4 more in the full profile.

07

Biomarkers

Short-chain fatty acid levels (e.g., butyrate in stool)Specific bacterial taxa abundance (e.g., Bifidobacterium, Faecalibacterium prausnitzii)Diversity indices (e.g., Shannon diversity)

Beyond the preview

Go deeper on Intestinal bacterium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal bacterium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call